News Daily News Certain Coronary Cases, Like STEMI, Tip Total Radiation Exposure Higher L.A. McKeown January 27, 2026
News Conference News ESC 2025 Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b Caitlin E. Cox August 31, 2025
News Daily News Some Ups, Some Downs in Proposed CMS Reimbursement for 2026, Cardiologists Say L.A. McKeown July 22, 2025
News Daily News No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits Michael O'Riordan July 14, 2025
News Daily News Myocardial Injury After Cardiac Surgery: Time for New hs-cTnT Thresholds? Yael L. Maxwell September 19, 2023
News Conference News ACC 2023 CRP More Predictive of Future Events Than LDL in Statin-Treated Patients Caitlin E. Cox March 14, 2023
News Conference News AHA 2022 RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl Todd Neale November 10, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Daily News New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT Caitlin E. Cox July 08, 2022
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2020 Shelley Wood November 30, 2020
News Conference News AHA 2020 OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients Todd Neale November 15, 2020
News Conference News AHA 2020 Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT Todd Neale November 15, 2020
News Daily News More Circulating Omega-3s May Boost Prognosis After STEMI Todd Neale October 26, 2020
News Conference News TCT 2020 Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT Todd Neale October 21, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
Presentation SCAI 2020 Reduction of Revascularization in Patients with Hypertriglyceridemia with Icosapent Ethyl: Insights from REDUCE-IT REVASC Presenter: Benjamin E. Peterson May 21, 2020
News Conference News SCAI 2020 Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data Caitlin E. Cox May 15, 2020
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020